Free Trial

Amarin (AMRN) Competitors

Amarin logo
$14.92 +0.32 (+2.19%)
Closing price 09/18/2025 04:00 PM Eastern
Extended Trading
$14.92 +0.01 (+0.03%)
As of 09/18/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMRN vs. TLRY, EVO, RCUS, NTLA, TRML, PHVS, XERS, GPCR, CVAC, and ZYME

Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Tilray Brands (TLRY), Evotec (EVO), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Tourmaline Bio (TRML), Pharvaris (PHVS), Xeris Biopharma (XERS), Structure Therapeutics (GPCR), CureVac (CVAC), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.

Amarin vs. Its Competitors

Amarin (NASDAQ:AMRN) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Amarin has higher revenue and earnings than Tilray Brands. Amarin is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$228.61M1.35-$82.18M-$3.67-4.07
Tilray Brands$210.48M6.59-$2.19B-$2.31-0.55

Amarin presently has a consensus price target of $12.00, suggesting a potential downside of 19.57%. Tilray Brands has a consensus price target of $1.94, suggesting a potential upside of 53.77%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts clearly believe Tilray Brands is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Tilray Brands
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Amarin has a net margin of -47.22% compared to Tilray Brands' net margin of -265.69%. Tilray Brands' return on equity of -6.83% beat Amarin's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-47.22% -21.18% -15.00%
Tilray Brands -265.69%-6.83%-5.45%

In the previous week, Tilray Brands had 16 more articles in the media than Amarin. MarketBeat recorded 18 mentions for Tilray Brands and 2 mentions for Amarin. Tilray Brands' average media sentiment score of 0.96 beat Amarin's score of 0.93 indicating that Tilray Brands is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tilray Brands
12 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

22.3% of Amarin shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 3.3% of Amarin shares are held by company insiders. Comparatively, 0.6% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amarin has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Summary

Tilray Brands beats Amarin on 11 of the 16 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMRN vs. The Competition

MetricAmarinMED IndustryMedical SectorNASDAQ Exchange
Market Cap$301.97M$3.12B$5.78B$10.28B
Dividend YieldN/A2.37%5.74%4.64%
P/E Ratio-4.0721.3676.9426.98
Price / Sales1.35475.60543.88128.54
Price / CashN/A45.3237.1760.63
Price / Book0.639.6913.836.37
Net Income-$82.18M-$52.92M$3.29B$271.46M
7 Day Performance-0.60%2.19%1.57%2.53%
1 Month Performance-5.69%8.96%6.87%9.42%
1 Year Performance24.62%10.84%81.59%30.16%

Amarin Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMRN
Amarin
0.5992 of 5 stars
$14.92
+2.2%
$12.00
-19.6%
+25.0%$301.97M$228.61M-4.07360
TLRY
Tilray Brands
3.0522 of 5 stars
$1.18
+5.4%
$1.94
+64.2%
-30.0%$1.23B$821.31M0.002,842
EVO
Evotec
1.8913 of 5 stars
$3.50
+0.9%
$5.40
+54.3%
+2.5%$1.23B$862.40M0.004,827Positive News
Gap Up
RCUS
Arcus Biosciences
2.0158 of 5 stars
$11.57
+0.4%
$21.14
+82.7%
-24.3%$1.23B$258M-3.65500Positive News
NTLA
Intellia Therapeutics
4.5054 of 5 stars
$11.57
+1.3%
$27.11
+134.3%
-28.5%$1.23B$57.88M0.00600Options Volume
Gap Up
TRML
Tourmaline Bio
0.9335 of 5 stars
$47.65
+0.1%
$45.65
-4.2%
+127.1%$1.22BN/A0.0044
PHVS
Pharvaris
2.4593 of 5 stars
$23.38
+0.8%
$34.00
+45.4%
+21.1%$1.21BN/A0.0030Positive News
XERS
Xeris Biopharma
2.8539 of 5 stars
$7.36
-1.7%
$7.08
-3.8%
+186.2%$1.21B$203.07M0.00290
GPCR
Structure Therapeutics
3.5124 of 5 stars
$20.20
-3.4%
$75.71
+274.8%
-39.3%$1.20BN/A0.00136Positive News
Gap Up
CVAC
CureVac
3.9341 of 5 stars
$5.36
+0.4%
$6.83
+27.5%
+62.6%$1.20B$579.18M5.56880Short Interest ↑
ZYME
Zymeworks
2.5704 of 5 stars
$15.93
+1.2%
$21.43
+34.5%
+31.7%$1.20B$122.87M-10.62460Positive News

Related Companies and Tools


This page (NASDAQ:AMRN) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners